Literature DB >> 27169576

Residual Kidney Function Decline and Mortality in Incident Hemodialysis Patients.

Yoshitsugu Obi1, Connie M Rhee1, Anna T Mathew2, Gaurang Shah1, Elani Streja1, Steven M Brunelli3, Csaba P Kovesdy4,5, Rajnish Mehrotra6, Kamyar Kalantar-Zadeh7,8,9.   

Abstract

In patients with ESRD, residual kidney function (RKF) contributes to achievement of adequate solute clearance. However, few studies have examined RKF in patients on hemodialysis. In a longitudinal cohort of 6538 patients who started maintenance hemodialysis over a 4-year period (January 2007 through December 2010) and had available renal urea clearance (CLurea) data at baseline and 1 year after hemodialysis initiation, we examined the association of annual change in renal CLurea rate with subsequent survival. The median (interquartile range) baseline value and mean±SD annual change of CLurea were 3.3 (1.9-5.0) and -1.1±2.8 ml/min per 1.73 m2, respectively. Greater CLurea rate 1 year after hemodialysis initiation associated with better survival. Furthermore, we found a gradient association between loss of RKF and all-cause mortality: changes in CLurea rate of -6.0 and +3.0 ml/min per 1.73 m2 per year associated with case mix-adjusted hazard ratios (95% confidence intervals) of 2.00 (1.55 to 2.59) and 0. 61 (0.50 to 0.74), respectively (reference: -1.5 ml/min per 1.73 m2 per year). These associations remained robust against adjustment for laboratory variables and ultrafiltration rate and were consistent across strata of baseline CLurea, age, sex, race, diabetes status, presence of congestive heart failure, and hemoglobin, serum albumin, and serum phosphorus levels. Sensitivity analyses using urine volume as another index of RKF yielded consistent associations. In conclusion, RKF decline during the first year of dialysis has a graded association with all-cause mortality among incident hemodialysis patients. The clinical benefits of RKF preservation strategies on mortality should be determined.
Copyright © 2016 by the American Society of Nephrology.

Entities:  

Keywords:  chronic hemodialysis; end stage kidney disease; end-stage renal disease; hemodialysis; hemodialysis adequacy; renal function decline

Mesh:

Year:  2016        PMID: 27169576      PMCID: PMC5118484          DOI: 10.1681/ASN.2015101142

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   10.121


  42 in total

1.  Role of residual renal function in phosphate control and anemia management in chronic hemodialysis patients.

Authors:  E Lars Penne; Neelke C van der Weerd; Muriel P C Grooteman; Albert H A Mazairac; Marinus A van den Dorpel; Menso J Nubé; Michiel L Bots; Renée Lévesque; Piet M ter Wee; Peter J Blankestijn
Journal:  Clin J Am Soc Nephrol       Date:  2010-10-28       Impact factor: 8.237

2.  Clinical practice recommendations for peritoneal dialysis adequacy.

Authors: 
Journal:  Am J Kidney Dis       Date:  2006-07       Impact factor: 8.860

3.  Effects of high efficiency post-dilution on-line hemodiafiltration or conventional hemodialysis on residual renal function and left ventricular hypertrophy.

Authors:  Helmut Schiffl; Susanne M Lang; Rainald Fischer
Journal:  Int Urol Nephrol       Date:  2012-12-07       Impact factor: 2.370

4.  Let us give twice-weekly hemodialysis a chance: revisiting the taboo.

Authors:  Kamyar Kalantar-Zadeh; Francesco G Casino
Journal:  Nephrol Dial Transplant       Date:  2014-04-29       Impact factor: 5.992

5.  Simplified calculation of body-surface area.

Authors:  R D Mosteller
Journal:  N Engl J Med       Date:  1987-10-22       Impact factor: 91.245

6.  Medicare program; End-Stage Renal Disease prospective payment system, quality incentive program, and Durable Medical Equipment, Prosthetics, Orthotics, and Supplies. Final rule.

Authors: 
Journal:  Fed Regist       Date:  2014-11-06

7.  Short-term effects of online hemodiafiltration on phosphate control: a result from the randomized controlled Convective Transport Study (CONTRAST).

Authors:  E Lars Penne; Neelke C van der Weerd; Marinus A van den Dorpel; Muriel P C Grooteman; Renée Lévesque; Menso J Nubé; Michiel L Bots; Peter J Blankestijn; Piet M ter Wee
Journal:  Am J Kidney Dis       Date:  2009-12-05       Impact factor: 8.860

8.  Association of initial twice-weekly hemodialysis treatment with preservation of residual kidney function in ESRD patients.

Authors:  Minmin Zhang; Mengjing Wang; Haiming Li; Ping Yu; Li Yuan; Chuanming Hao; Jing Chen; Kamyar Kalantar-Zadeh
Journal:  Am J Nephrol       Date:  2014-08-23       Impact factor: 3.754

9.  Equations for normalized protein catabolic rate based on two-point modeling of hemodialysis urea kinetics.

Authors:  T A Depner; J T Daugirdas
Journal:  J Am Soc Nephrol       Date:  1996-05       Impact factor: 10.121

10.  Recovery of renal function among ESRD patients in the US medicare program.

Authors:  Sumit Mohan; Edwin Huff; Jay Wish; Michael Lilly; Shu-Cheng Chen; William M McClellan
Journal:  PLoS One       Date:  2013-12-17       Impact factor: 3.240

View more
  57 in total

Review 1.  Incremental dialysis for preserving residual kidney function-Does one size fit all when initiating dialysis?

Authors:  Anna T Mathew; Yoshitsugu Obi; Connie M Rhee; Jason A Chou; Kamyar Kalantar-Zadeh
Journal:  Semin Dial       Date:  2018-05-07       Impact factor: 3.455

2.  Results of the HEMO Study suggest that p-cresol sulfate and indoxyl sulfate are not associated with cardiovascular outcomes.

Authors:  Tariq Shafi; Tammy L Sirich; Timothy W Meyer; Thomas H Hostetter; Natalie S Plummer; Seungyoung Hwang; Michal L Melamed; Tanushree Banerjee; Josef Coresh; Neil R Powe
Journal:  Kidney Int       Date:  2017-07-21       Impact factor: 10.612

3.  Prediction equation for calculating residual kidney urea clearance using urine collections for different hemodialysis treatment frequencies and interdialytic intervals.

Authors:  Yoshitsugu Obi; Kamyar Kalantar-Zadeh; Elani Streja; John T Daugirdas
Journal:  Nephrol Dial Transplant       Date:  2018-03-01       Impact factor: 5.992

4.  Residual kidney function in twice-weekly hemodialysis: irreplaceable contribution to dialysis adequacy.

Authors:  Yu-Ji Lee; Connie M Rhee; Kamyar Kalantar-Zadeh
Journal:  Ann Transl Med       Date:  2018-08

Review 5.  Renal Replacement Therapy and Incremental Hemodialysis for Veterans with Advanced Chronic Kidney Disease.

Authors:  Kamyar Kalantar-Zadeh; Susan T Crowley; Srinivasan Beddhu; Joline L T Chen; John T Daugirdas; David S Goldfarb; Anna Jin; Csaba P Kovesdy; David J Leehey; Hamid Moradi; Sankar D Navaneethan; Keith C Norris; Yoshitsugu Obi; Ann O'Hare; Tariq Shafi; Elani Streja; Mark L Unruh; Tushar J Vachharajani; Steven Weisbord; Connie M Rhee
Journal:  Semin Dial       Date:  2017-04-18       Impact factor: 3.455

Review 6.  Volume Balance and Intradialytic Ultrafiltration Rate in the Hemodialysis Patient.

Authors:  Jason A Chou; Kamyar Kalantar-Zadeh
Journal:  Curr Heart Fail Rep       Date:  2017-10

Review 7.  Modeling longitudinal data and its impact on survival in observational nephrology studies: tools and considerations.

Authors:  Elani Streja; Leanne Goldstein; Melissa Soohoo; Yoshitsugu Obi; Kamyar Kalantar-Zadeh; Connie M Rhee
Journal:  Nephrol Dial Transplant       Date:  2017-04-01       Impact factor: 5.992

Review 8.  Incremental and infrequent hemodialysis: a new paradigm for both dialysis initiation and conservative management.

Authors:  Connie M Rhee; Mehrdad Ghahremani-Ghajar; Yoshitsugu Obi; Kamyar Kalantar-Zadeh
Journal:  Panminerva Med       Date:  2017-01-13       Impact factor: 5.197

9.  Preserving Residual Kidney Function in Hemodialysis Patients-Back in the Spotlight.

Authors:  Angela Yee-Moon Wang
Journal:  J Am Soc Nephrol       Date:  2016-08-04       Impact factor: 10.121

10.  Predialysis Kidney Function and Its Rate of Decline Predict Mortality and Hospitalizations After Starting Dialysis.

Authors:  Melissa Soohoo; Elani Streja; Yoshitsugu Obi; Connie M Rhee; Daniel L Gillen; Keiichi Sumida; Danh V Nguyen; Csaba P Kovesdy; Kamyar Kalantar-Zadeh
Journal:  Mayo Clin Proc       Date:  2018-07-04       Impact factor: 7.616

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.